The object of the invention is a new type of B7-H3 binding molecule which can be combined with human and non-human B7-H3, especially the reaction molecule which intersects with non-human primate B7-H3.A month ago The invention belongs to B7-H3 binding molecule, including humanized and / or dehumanized variable light chain domains and / or variable heavy chain domains, which are administratively immune to the receptor. The invention is made by two, three or more specific molecules combined with B7-H3, including two organisms, bits, two antibodies and trivalent binding molecules,These include: (1) a variable domain connected to B7-H3 and (2) a domain that can combine molecular entries on the surface of a galaxy. The object of the invention is a pharmaceutical compound containing B7-H3 binding molecule,And methods involving the use of this molecule bound to B7-H3 in the treatment of cancer and other diseases and diseases. The invention belongs to a molecule, which comprises a B7-H3 human binding domain from an anti-human B7-H3 antibody combination to at least a part of a drug (a "b7-h3-adc"). The invention is directed at pharmaceutical compounds containing b7-h3-adcs and methods for treating cancer and other diseases and diseases with b7-h3-adc.La invención se dirige a moléculas de unión a B7-H3 novedosas capaces de unirse a B7-H3 humanas y no-humanas, y en particular a moléculas que son un reactivo cruzado con B7-H3 de un primate no humano (p. ej., un mono cynomolgus). La invención pertenece a las moléculas de unión a B7-H3 que comprenden Dominios de Cadena Ligera Variable y/o Cadena Pesada Variable (VH) que se han humanizado y/o deshumanizado que presentan una inmunogenicidad reducida en la administración a los sujetos receptores. La invención pertenece a moléculas biespecíficas, triespecíficas o multiespecíficas de unión a B7-H3, que incluyen diacuerpos biespecíficos, BiTEs, anticuerpos biespecíficos, moléculas de unión trivalentes, etc. que comprenden: (i) Dominios
